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Abstract
Hot flashes are experienced by about 52% of perimenopausal women. After breast cancer,
this may increase to 70%. The use of hormone replacement therapy is not recommended in
women who have had breast cancer; therefore, alternatives are required to help relieve hot
flashes. This study was conducted to assess the efficacy of relaxation training in reducing the
incidence of hot flashes in women with primary breast cancer. This was a randomized
controlled trial of 150 women with primary breast cancer who experienced hot flashes. The
intervention group received a single relaxation training session and was instructed to use
practice tapes on a daily basis at home for one month; the control group received no
intervention. Outcomes were incidence and severity of flashes using a diary and validated
measures of anxiety and quality of life. The incidence and severity of hot flashes, as recorded
by diaries, each significantly declined over one month (P< 0.001 and P¼ 0.01,
respectively), compared with the control group. Distress caused by flashes also significantly
declined in the treatment group over one month (P¼ 0.01), compared with the control group.
There were no significant differences between the treatment group and the control group at
three months and no changes in anxiety or quality-of-life measures. Relaxation may be
a useful component of a program of measures to relieve hot flashes in women with primary
breast cancer. J Pain Symptom Manage 2008;35:397e405.  2008 U.S. Cancer Pain
Relief Committee. Published by Elsevier Inc. All rights reserved.
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Introduction
Hot flashes are experienced by approxi-
mately 52% of perimenopausal women.1 After
breast cancer, this may increase to 70% of
women.2,3 Hormone replacement therapy is
no longer preferred for the treatment of this
problem generally,4e6 and is contraindicated
in women with breast cancer because of an
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women have been turning to the use of
complementary and alternative medicines8,9
for menopausal problems and seeking other
nonpharmacological strategies.
The cause of hot flashes is still unknown and
appears to be due to a change in the hypotha-
lamic control of temperature regulation. The
variation in core body temperature that takes
place before either sweating or shivering
occurs is reduced in symptomatic postmeno-
pausal women from 0.4C 0.18 to
0.0C 0.06, which means that women are
more sensitive to small variations in tempera-
ture; a number of neurotransmitters have
been postulated to be involved in this process,
including serotonin,10 beta-endorphins, and
norepinephrine.11,12
There may be a link between postmeno-
pausal changes and a norepinephrine-mediated
cause of flashes, as estrogen levels affect the
number of adrenergic receptors in the brain,
which, in turn, modulate the amount of norepi-
nephrine available.12 The relaxation response
directly influences central norepinephrine,13
and it may be postulated that relaxation might
have a favorable effect on flashes through the
modulation of norepinephrine release.
Swartzman et al.14 have demonstrated that
women subjected to stress experience an in-
creased number of flashes over a 24-hour pe-
riod. The fact that stress potentiates, rather
than precipitates, flashes suggests that there
is not a direct sympathetic response to stress,
but supports the view that the flash mechanism
is mediated via a central mechanism and
would be consistent with norepinephrine in-
fluences on the brain.
A number of small studies have provided
evidence to support the use of relaxation to re-
duce flashes.15e20 A recent work by Nedstrand
et al.21 comparing relaxation with estrogen re-
placement concluded that relaxation is a useful
alternative treatment for vasomotor symptoms
in postmenopausal women. However, these
studies are all small and there is a need for
a large-scale, randomized, controlled trial to
investigate the use of relaxation to reduce
hot flashes in postmenopausal women and,
in particular, for women with breast cancer,
for whom replacement estrogen is contraindi-
cated. In this article, we report the results of
such a trial.Methods
We recruited 150 women from three breast
cancer follow-up clinics in a specialist cancer
hospital in the southeast of England. Inclusion
criteria were postmenopausal women diag-
nosed with primary breast cancer and suffering
from menopausal hot flashes. Any level of
severity was accepted for inclusion in the trial
as long as the women found the flashes to be
troublesome. Postmenopausal was defined as
six months without menstruation. This crite-
rion may have included some women for
whom menstruation returned at a later date,
but was chosen as it included women with che-
motherapy-induced menopause, which ap-
pears to be associated with particularly severe
flashes. The women also were required to be
able to complete written records in English.
Women using estrogen therapy, aromatase
inhibitors, or any other hormone therapies,
except tamoxifen, were excluded. Those tak-
ing remedies or prescription medicines likely
to have an impact on hot flashes, such as
acupuncture, venlafaxine, progesterones, or
clonidine, also were excluded. Remedies for
which there is no evidence of efficacy, such
as evening primrose oil, increased dietary soy,
starflower oil, multivitamins, and reduced
caffeine intake, were not exclusions. Ethical
approval for the study was given by the local
hospital ethics committee and written consent
was obtained from the participants.
Women attending the clinics were asked if
they were experiencing hot flashes and
whether they were interested in a study to see
if relaxation training could reduce their
flashes. Following randomization, in those
allocated to receive the intervention, an ap-
pointment for relaxation training was booked
for the following week on completion of the
baseline diary. Day 0 was taken as the day of
relaxation training, and in the control group,
Day 0 was the day after completion of the diary.
We audited the number of women eligible for
the study attending clinics over the course of
one month. Of the 79 potentially eligible
women 54 (68%) were experiencing hot
flashes. Of those with flashes, 13 (24%) were
taking other treatments for flashes and 20
(37%) said that flashes were not troublesome,
leaving 21 (39%) women who were eligible for
entry to the study. Of the eligible women, nine
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entering are given in the flow diagram (Fig. 1).
Intervention
Women randomized to the treatment arm of
the study were seen by the occupational thera-
pist for a single, hour-long, one-to-one session
of training about relaxation. The trainingincluded the basics of stress management; writ-
ten information about stress; and a session of
relaxation using deep breathing techniques,
muscle relaxation, and guided imagery (used
to enhance the relaxation effect). An audio-
tape of the trainer’s voice talking through
the same relaxation session was given to the
women to use at home. A second reinforcingEligible for study n=315
(estimated from one month audit)
Reasons for 
nonparticipation
Randomized n=150
relaxation n=74 control n=76
Consent withdrawn n=13
Not like the diary n=1
Flashes stopped n=1
Reminder of cancer n=1
Illness n=2
No reason given n=8
Day 0 (relaxation training)
relaxation taught n=61
Day 28
withdrawn n=11
no time for relaxation n=1
holiday intervened n=1
family reasons n=1
no reason given n=8
Day 84
withdrawn n=4
family reasons n=1
no reason given n=3
completion of trial at three months n=46
Consent withdrawn n=12 
Not like the diary n=1
Too busy n=2
Family reasons n=2
Reminder of flash problem n=1
No reason given n=6 
Day 0 (return of diaries)
control n=64
Day 28
withdrawn n=10
family reasons n=1
too busy to do diary n=1
no reason given n=8
Day 84
withdrawn n=3
periods returned n=1
moved house n=1
no reason given n=1
completion of trial at three months n=51
completion of trial at one month n=50 completion of trial at one month n=54
•
•
•
•
•
•
•
Want other
treatment (15%)
Live too far
away (5%)
Would forget
diary (9%)
Not like
relaxation (5%)
Too busy (5%)
No reason
given (9%)
Might come
back later (9%)
Fig. 1. Patient recruitment and follow up.
400 Vol. 35 No. 4 April 2008Fenlon et al.training session was offered to those who chose
to take it up, but was accepted by only two
women. The women were then asked to use
the tape provided to undertake a 20-minute
relaxation once per day for at least a month.
No instruction was given regarding the use of
the relaxation tapes after this time. Records
of relaxation during the first month were
returned by 69% women in the intervention
group. Half of the women that returned these
records practiced relaxation every day and the
rest practiced at least every other day.
The baseline diary and questionnaires were
given out by the recruiting research nurse,
whereas the diary and questionnaires at one
and three months were posted, with specific
instructions as to when to complete them.
One reminder phone call was made a week
after the expected return of the diaries and
questionnaires.
The care of women randomized to the con-
trol arm of the study was given attention with
regards to their flashes, but otherwise were
given no other intervention for their flashes.
The attention consisted of spending time
with a specialist nurse, discussing hot flashes
and menopause management. This took the
form of a general discussion on menopause
management, including hot flashes, aging, vag-
inal dryness, and bone health. Women were
advised about lifestyle measures to improve
their health, such as diet, exercise, vaginal
moisturizers, and stress reduction. They were
asked not to commence any new therapies spe-
cifically for hot flashes during the course of the
trial.
Outcomes
The incidence of flashes was measured using
a diary, kept by the women, of every flash as it
occurred over the period of one week. Diaries
have been recommended for use in hot flash
research by a number of researchers.22,23 The
women also gave a measure of the severity of
each flash using predefined categories based
on work by Finck et al.,24 who defined hot
flashes using interviews gathered from women
with breast cancer. The definition described
four domains of flashes: length of flash; physi-
cal manifestation; emotional response and be-
havioral response. For each of these domains,
four levels of severity (graded 1e4) were de-
scribed using the descriptors outlined by Fincket al.24 to ensure that all women were using the
same definitions of severity. The maximum
possible score per flash was, therefore, 16. In
the diary, a space was allocated for women to
record if they found anything that helped their
flashes.
The distress caused by flashes was measured
using the Hunter menopause scale.25 Women
scored from zero to ten the level of distress
due to flashes; the degree to which flashes
were perceived as a problem; and the degree
to which they were perceived to interfere
with everyday life. We also gathered data on
quality of life using the Functional Assessment
of Cancer Therapy26 with the endocrine sub-
scale (FACT-ES),27 and anxiety, which was
measured using the Spielberger State/Trait
Anxiety Index (STAI).28 All measures were
completed at baseline, and one and three
months after relaxation training. One month
was chosen as it was felt that this was when
maximum benefit was likely to be gained
from this intervention. Flashes were measured
again at three months, as any intervention that
is to be clinically relevant needs to be sustained
over a period of months.
Sample Size
Sample size was based on pilot data20 show-
ing that eight women experienced a 30%
reduction in flashes. Women were recruited
to the pilot study in the same way as in the
main study. This group of 16 women had
a mean of five flashes per day. For 90% power
and 5% significance to detect a reduction in
incidence of flashes of 30%, 43 women were
required in each arm of the trial (assuming
a mean number of five flashes per day, SD 3;
two-sided test). To allow for a 30% dropout
rate, as found in the pilot study,20 the intended
accrual was 150 patients in total. This number
agrees with that suggested by Sloan et al.,23
reporting data from a number of studies on
women with flashes, who state that at least 50
patients per treatment arm are required to
provide sufficient power to detect a clinically
meaningful change in hot flash activity.
Randomization
An independent trials office, accessed by tele-
phone, was responsible for randomization of
patients to relaxation training or to the control
group. A computer-generated randomization
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to clinic site andwhether the patient was over or
under 50 years of age. The women were re-
cruited by a specialist breast care nurse (DF),
who did not have access to the randomization
lists. Recruitment took place over a period of
15 months.
Statistical Methods
We summed the total number of flashes that
occurred over the period of one week. Severity
of each flash was the sum of the four domains
of flashes. The mean severity per flash was
used in the analysis to prevent conflation
with incidence of flashes. Levels of distress us-
ing the Hunter menopause scale were given as
a simple score from 0e10. We summarized the
FACT-ES quality-of-life questionnaire by calcu-
lating total quality-of-life score, as described
in the scoring manual.29 State and trait anxiety
were calculated according to the STAI man-
ual.30 We compared median scores for changein all outcome measures between the groups
using the ManneWhitney U test, because dis-
tributions of change scores were skewed. Anal-
ysis was undertaken on the basis of ‘‘intention
to treat,’’ with all randomized women contrib-
uting data included in the analysis. No imputa-
tion of missing data was done. As multiple tests
were carried out on the data, a cutoff for statis-
tical significance of P< 0.01 was used
throughout.
Results
Participants and Follow Up
Of 150 women recruited to the trial, 104
women completed the trial to the primary end-
point at one month and 97 completed all three
months. Reasons for noncompletion are
shown in Fig. 1. The women ranged in age
from 36 to 77 years and the majority were
white, British, and married (Table 1). ATable 1
Baseline Demographics and Clinical Characteristics
Characteristics Category
Relaxation Group
(n¼ 76) (%)
Control Group
(n¼ 74) (%)
Age (median and interquartile range) 54.9 (51.9e59.0) 55.4 (51.6e60.3)
Marital status No current partner 18 (24) 19 (26)
Married/partner 54 (72) 50 (67)
Missing data 4 (5) 0 (0)
Ethnic origin Caucasian 71 (93) 72 (97)
Other (including mixed race) 5 (6) 2 (2)
Time since diagnosis Less than 2 years 20 (26) 33 (45)
2e5 years 26 (34) 20 (27)
Over 5 years 30 (39) 21 (28)
Time since last menstruation Less than one year 8 (11) 10 (14)
1e2 years 13 (17) 10 (14)
2e5 years 19 (25) 15 (20)
More than 5 years 36 (47) 39 (53)
Currently taking tamoxifen 45 (59) 38 (51)
Had chemotherapy 35 (46) 39 (53)
Had oophorectomy 3 (4) 13 (18)
Taking any other treatment or medication 29 (38) 29 (39)
Other remedies for hot flashes 11 (14) 17 (23)
Incidence and severity of flashes from diaries (median and interquartile range)
Flashes per week 31.5 (20.00e45.00) 37.0 (20.00e81.00)
Severity per flash 4.7 (3.5e5.9) 4.7 (3.0e6.0)
Hunter menopause scale (median and interquartile range)
Distress due to flashes 5.0 (2.0e6.0) 5.0 (4.0e7.0)
Problem caused by flashes 5.5 (4.0e7.3) 6.0 (4.0e7.8)
Interference to daily life by flashes 3.0 (2.0e6.0) 3.0 (1.3e6.0)
FACT-ES (mean and standard deviation)
Total score 170 (152.8e178.3) 168.2 (149.3e183.0)
State-Trait Anxiety Index (mean and standard deviation)
State anxiety 37 (30e44) 35 (27e48)
Trait anxiety 40.5 (34.2e48) 37 (31.7e47)
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remedies for hot flashes. These were equally
distributed between the groups and were
remedies for which there is no evidence of
benefit, including evening primrose oil,14
soy,6 starflower oil,2 multivitamins,3 and re-
duced caffeine intake.1 There were no signifi-
cant differences in clinical characteristics or
outcome measures between the groups at base-
line, except for oophorectomy. The analysis
was recalculated excluding all women with
oophorectomy. This resulted in minor differ-
ences, which did not affect the overall conclu-
sions. Although prompted, there were no
records made in the diaries of new treatments
for flashes being taken up during the course of
the study. The mean wait time for relaxation
training was two weeks.
Comparison Between Relaxation and Control
To test the effectiveness of relaxation, we
compared the change in flashes over time
between the two groups (Table 2). After one
month, there was a median improvement of
seven flashes per week (22% improvement)
in the relaxation group; this was significant
when compared with the change in the control
group (<0.001) (Fig. 2). The severity of flashes
also improved significantly when compared to
the control group, which experienced nochange (P¼ 0.01). Apparent improvements
in both the number and severity of flashes in
the relaxation group at three months were
not significant (P¼ 0.06 and P¼ 0.05, respec-
tively) (Fig. 3). When examining the impact
of flashes on the women’s lives over one
month, the distress due to flashes was seen to
improve (P¼ 0.01), whereas the improvement
in the extent to which women thought flashes
were a problem and how much flashes inter-
fered with daily life did not reach statistical sig-
nificance (P¼ 0.06 and P¼ 0.09, respectively).
Relaxation did not appear to be more benefi-
cial in different treatment or age groups, al-
though the numbers in the study were
insufficient to detect significant differences
in subgroups. No statistically significant
changes were seen in either state or trait anxi-
ety on the STAI, nor on scores on the FACT-ES.
Discussion
The use of relaxation training reduced both
the incidence and the severity of hot flashes
and, possibly more importantly, the conse-
quent distress in women with breast cancer
one month after training with relaxation tech-
niques. Although the median reduction of five
per day to four per day may appear small, this
may reflect a real benefit for some women,Table 2
Median Scores for Change in Number, Severity, and Distress Due to Flashes, State and Trait Anxiety,
and Quality of Life at One and Three Months After Treatment
Item
Relaxation
Group
(median)
Control
Group
(median)
Median
Difference
95%CI for
Median
Difference
Manne
Whitney
test, P-Value
One month after randomization (n¼ 104) (n¼ 50) (n¼ 54)
Improvement in number of flashes per week 7 1 7 4, 11 <0.001*
Improvement in severity per flash 0.47 0 0.54 0.11, 1.01 0.01*
Improvement in distress due to flashes 1 0 1 0, 2 0.01*
Improvement in problem due to flashes 1 1 1 0, 1 0.06
Improvement in interference to daily life due to flashes 0 0 1 0, 1 0.09
Improvement in trait anxiety 0 2 1 4, 1 0.24
Improvement in state anxiety 1 0 1.0 4.0, 2.0 0.51
Change in quality of life (FACT-ES) 0.38 0.33 0.12 4.06, 4.65 0.94
Three months after randomization (n¼ 97) (n¼ 46) (n¼ 51)
Improvement in number of flashes per week 11 4 5 0, 10 0.06
Improvement in severity per flash 0.55 0.08 0.56 0.02, 1.18 0.05
Improvement in distress due to flashes 0 0 0 1, 1 0.66
Improvement in problem due to flashes 1 0.5 0 0, 1 0.21
Improvement in interference to daily life due to flashes 0 0 1 0, 1 0.11
Improvement in trait anxiety 1 1 1.0 2.0, 3.0 0.72
Improvement in state anxiety 0 2 2.0 2.0, 5.0 0.31
Change in quality of life (FACT-ES) 5.2 3.5 1.5 7.0, 4.4 0.62
All negative numbers indicate the measure is becoming worse.
*Indicates statistical significance.
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relevance of this for women is supported by
the significant reduction in the level of distress
reported due to flashes. It may be that the
number of flashes alone is less important
than the severity of the flash, or the combina-
tion of number and severity of flashes, in terms
of the distress caused to the individual. The
majority of those women who completed the
study managed to practice relaxation on a fre-
quent and regular basis, suggesting that this
form of relaxation may be a useful technique
that some women find acceptable to use for
themselves, although it is possible that those
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Fig. 2. Change in number of flashes (median and
interquartile range) per week after one month.
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Fig. 3. Change in number of flashes (median and
interquartile range) per week after three months.women who did not find relaxation acceptable
were among those who were not selected for
the study.
There was an apparent imbalance in the
baseline number of flashes, with the interven-
tion group experiencing less than the control
group, although this was not a statistically sig-
nificant difference. These baseline differences
may have contributed to obscure any benefit
due to the intervention, which may suggest
that the real benefit of relaxation is greater
than demonstrated.
The reduction in incidence was apparently
not sustained after three months. This may be
due to the trial design. The women were asked
to practice the relaxation session daily for one
month and then it was left to them to decide
whether or not to continue. Records of relaxa-
tion were also not maintained after this time.
The reason for this decision was to maximize
the intervention at the one-month time point,
but the consequence may have been to weaken
the findings at three months. The level of inter-
vention was also minimal, being comprised of
only a single training session, to emulate clinical
reality where resources are scarce. More inten-
sive trainingmay result in a longer lasting effect.
There were no differences seen in quality of
life, as measured by the FACT-ES, between the
relaxation and control groups, either before or
after intervention. As the FACT-ES measure
was developed for women undergoing breast
cancer treatment, it is heavily weighted toward
the presence of treatment side effects and
symptomatology and so may have been insuffi-
ciently sensitive to detect quality-of-life issues
associated with flashes.
This sample comprised a population mainly
of white British women in southeast England.
Findingsmay not be generalizable to other pop-
ulations. The sample was also biased towards
those who had the midrange of severity of
flashes. Women with mild flashes chose not to
participate in the study and women with severe
flashes were frequently taking other remedies
for flashes, which excluded them from the trial.
The wait time for relaxation trainingmeant that
baseline to Day 0 was a mean of two weeks lon-
ger in the treated group than the control
group. However, as no significant change was
seen in flash incidence in the control group
over three months, this was not thought to
influence the outcome.
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were more than six months without menstrua-
tion in order to include women experiencing
a chemotherapy-induced menopause, which
often is accompanied by particularly severe
flashes. However, there was a risk that menstru-
ation would return in some of these women.
This happened in only one case, which was
in the control arm. This woman had frequent
and severe flashes, which ceased on the return
of menstruation. It is possible that this case
weakened the outcome of the study.
Although self-report measures of hot flashes
have been shown to correspond well to labora-
tory monitoring methods of measuring
flashes,31 the use of diaries may introduce
bias due to participant’s willingness to please,
or to the control group’s disappointment at
not being given active treatment. Further-
more, as there was no placebo, it could be sug-
gested that the benefit was due to placebo
response. Some authors report a placebo ef-
fect for trials with hot flashes.23 Designing
a placebo intervention for this kind of study
is problematic, as there is no inactive form of
relaxation training. It has been suggested
that a major component of placebo is the at-
tention that participants receive due to the
therapeutic relationship between the partici-
pant and the researcher,32 in this case an expe-
rienced breast care nurse. All the women spent
time before randomization with the researcher
who was recruiting women to the study. This
recruitment interview involved assessing wom-
en’s experience of flashes and discussion of
management strategies, and the relationship
was maintained through the trial by means of
the maintenance of the diaries and follow-up
phone calls and correspondence. In this way,
it could be suggested that all the women ob-
tained the benefits that would have been
achieved from placebo. An alternative explana-
tion might be that the control group did not
achieve a placebo response due to disappoint-
ment in not getting the relaxation training.
Future work would need to address the issue
of the placebo effect.
Conclusions
This study showed a small, but significant re-
duction in the incidence, severity, and distress
caused by hot flashes in women with breastcancer who underwent training in relaxation.
Although doubts remain about the possibility
of a placebo effect and the fact that this effect
was small, there may be real benefits for some
women who use relaxation for the relief of hot
flashes. Future work might focus on finding
ways to enhance this effect, identifying sub-
groups who might achieve greater benefit
and exploring what women perceive to be
the real benefits of this kind of approach to
managing hot flashes.
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